Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012
Statements of Operations and Comprehensive Income (Loss) [Abstract]
Net sales	$ 5,576,403	$ 7,431,486	$ 10,235,857	$ 11,971,928
Costs of sales	(3,754,150)	(4,690,963)	(6,747,978)	(7,644,174)
Gross profit	1,822,253	2,740,523	3,487,879	4,327,754
Selling expenses	(622,855)	(548,179)	(1,282,469)	(1,094,232)
Administrative expenses	(997,469)	(680,232)	(1,979,059)	(1,221,236)
Depreciation and amortization	(52,239)	(14,763)	(116,554)	(26,429)
Income from operations	149,690	1,497,349	109,797	1,985,857
Other income	40,067		43,335
Interest income	18,813	148,252	26,146	169,453
Interest expense	(39,376)	(368,782)	(254,435)	(741,869)
Amortization of discount on notes		(690,903)	(402,394)	(1,381,806)
Income (loss) before income taxes	169,194	585,916	(477,551)	31,635
Income tax expense	(53,512)	(313,502)	(85,611)	(430,198)
Net income (loss)	115,682	272,414	(563,162)	(398,563)
Net loss attributable to non-controlling interest	(2,482)		(4,997)
Net income (loss) attributable to Tanke Biosciences Corporation	118,164	272,414	(558,165)	(398,563)
Net income (loss)	115,682	272,414	(563,162)	(398,563)
Other comprehensive income, net of tax:
Foreign currency translation adjustments	380,569	98,471	512,539	210,957
Comprehensive income (loss)	496,251	370,885	(50,623)	(187,606)
Comprehensive income (loss) attributable to non-controlling interest	15		(1,520)
Comprehensive income (loss) attributable to Tanke Biosciences Corporation	$ 496,236	$ 370,885	$ (49,103)	$ (187,606)
Income (loss) per common share:
Basic and diluted	$ 0.01	$ 0.02	$ (0.04)	$ (0.03)
Weighted average number of common shares used in computation
Basic and diluted	13,324,083	13,324,083	13,324,083	13,324,083